Repositories Lunch Meeting, Day 1

Slides:

Advertisements

Similar presentations

The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing AUSTRALIAN ADNI. July 2010 UPDATE.

Advertisements

DIAN Treatment Trials An Update Sunday February 10, :00 to 6:00 PM CST Presented by Randall Bateman MD DIAN Therapeutic Trials Unit Director DIAN.

Registries, Databases & Clinical Networks David J Burn Newcastle University.

Evdokia Anagnostou, MD Clinician Scientist, Holland Bloorview Kids Rehab Hospital Associate Professor, Department of Pediatrics University of Toronto Canada.

PRoBaND Parkinson’s Repository of Biosamples and Networked Datasets History Hypotheses Overview Linkage to other studies Funded by Parkinson’s UK Dr Donald.

Tracking the East Midlands contribution to PD-PROBAND Nin Bajaj Clinical Director NPF International Centre of Excellence in PD, East Midlands Trent CLRN.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April

CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.

EPAD update José Luis Molinuevo Worldwide-ADNI Update Meeting Friday, July 17, 2015 Washington, D.C.

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.

Anticipated FY2016 Appropriations Agency$ Million NIH200 Cancer70 Cohort130 FDA10 Office of the Natl Coord. for Health IT (ONC) 5 TOTAL215 Mission: To.

COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.

CPTR Overview CPTR 2012 Workshop October 2-4, 2012.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE Michael W. Weiner.

PharmaCog WP5 / E-ADNI. Enrollment and follow-ups Clinical sites Maximum Minimum PATIENTS EXPECTED.

The European Prevention of Alzheimer's Dementia (EPAD) project aims to develop an infrastructure that efficiently enables the undertaking of adaptive,

Alzheimer’s Disease Today and Tomorrow First case reported in 1906 Reported by Alois Alzheimer Patient Augusta D. first treated at 46 years old Paranoia,

NCRAD Update Tatiana Foroud, Ph.D. Indiana University.

ADNI PPSB Update WW ADNI Meeting 22 July, An Eventful Year… Successful renewal of ADNI (ADNI-3) PPSB had an opportunity to contribute – PPSB/Biomarker.

Myotonic Dystrophy Research: What’s Next

Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease Mirjana Babić.

José L Molinuevo, Craig Ritchie, Miia Kivipelto

TMIST A Breast Cancer Screening Trial

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Rosa Maria Moresco University of Milan Bicocca

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Million Veteran Program Data Marts and Data Access

Use of Amyloid PET Scan in Early Diagnosis of Alzheimer’s Disease in a Secondary Care Memory Clinic Niki Schoonenboom, MD PhD1, Mohammed Akarriou, MD2;

Dementia Research and Enterprise at Liverpool John Moores University

CORRELATION OF BIOMARKERS FOR AXONAL DEGENERATION WITH RETINAL NERVE FIBER LAYER THICKNESS AND DISABILITY IN DIFFERENT PHASES OF MULTIPLE SCLEROSIS UZUNKOPRU.

Dementia: from molecules to minds

Worldwide-ADNI Update Meeting Fairmont Royal York Hotel

NeuroMET and biomarkers

Data challenges in the pharmaceutical industry

Cognitive Data in the Parkinson’s Progression Marker Initiative: Comparison of Normative Data Approaches Kathryn A. Wyman-Chick, Matthew J. Barrett, Phillip.

Volume 2, Issue 1, Pages (January 2016)

Imaging AD Progression Amyloid Imaging Agents.

THE PARKINSON’S PROGRESSION MARKERS INITIATIVE

Parkinson’s Progression Markers initiative

Leslie M Shaw Perelman School of Medicine University of Pennsylvania

Wearables and Digital Sensor Technology

PPMI in the Medical Literature

ppmi EPIgenetics Andy Singleton and Dena Hernandez

IDEAS Study. IDEAS Study IDEAS Research Team Study Overview.

Martin Tuchyňa Towards an INSPIREd e-reporting & INSPIRE priority datasets in Slovakia INSPIRE conference ,

PPMI Beyond 2018.

PPMI Pathology Core Tatiana Foroud & Tom Montine.

CSF αlpha-synuclein is not a good diagnostic and progression marker (alone)

Participation in clinical trials

Phenoconversion in PPMI

PPMI – GOALS 2019 Ken Marek PPMI Annual Meeting May 3, 2018

Progress report on the SAI Capacity Development Database

José L Molinuevo, Craig Ritchie, Miia Kivipelto

National Institute of Mental Health and Neurosciences

The EMPIR NeuroMET project

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

DAT Imaging in a cohort of p.A53T SNCA PD patients versus typical PD

Boston Naming Test predicts deterioration of cerebrospinal fluid biomarkers in pre-symptomatic Alzheimer’s disease Charleen Wilder, MA, Kristina Moncrieffe,

2017 Parkinson Disease.

Gait Sub study Anat Mirelman PhD.

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.

Multidisciplinary Management in Non-Small Cell Lung Cancer (NSCLC)

Aaron Ritter MD Cleveland Clinic Lou Ruvo Center for Brain Health

Discovery From Data Repositories H Craig Mak Nature Biotechnology 29, 46–47 (2011) 2013 /06 /10.

Schematic overview of the immuno‐infrared‐sensor, the assay read‐out, and BioFINDER and ESTHER study design Schematic overview of the immuno‐infrared‐sensor,

ADNI 3 UPDATE MICHAEL WEINER.

Columbia University Medical Center

European Prevention Alzheimer’s Dementia

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER.

Presentation transcript:

Repositories Lunch Meeting, Day 1 Wall Hub Data Flow Group – Day 2, 11-12pm Riverview Dining Area Coordinator Session – Day 2, 11-12pm Pathology Core Lunch Meeting (International sites) – Day 2 Old Slip Studio Wearables Lunch Meeting, Day 2 Front Studio

Break out session 1 Wearable Sensors – Verily (U.S. sites) Bill Marks, Tatiana Foroud The Forum Digital Sensor Technology – Roche (International sites) Kirsten Taylor, Vanessa Arnedo Front Studio Navigating PPMI Database Chelsea Caspell-Garcia Water Studio

Break out Session 2 PPMI Working Groups Biologics Imaging -Provide an update on analysis of Core CSF assays for a-Syn, A-beta42, tau and P-tau in CSF -Provide information about ongoing work in BioFIND and PPMI to analyze novel markers e.g., RNA, epigenetics, etc -Summarize ongoing biomarker discovery work presented at Biologics Group conference calls Imaging -Share amyloid PET data -Predictors of disease progression, genotype and phenotype -Added value of baseline DTI metrics and SN FreeWater to PD classification compared to DAT imaging -Added value of baseline DTI metrics and SN FreeWater to predication of 1-year (and 2-year) change in motor symptoms compared to DAT imaging -Potential effects of age-of-diagnosis on these models -Update on resting state analysis with next steps -Update on free water analysis with next steps

Break out Session 2 PPMI Working Groups Cognition/Neuropsychiatric -Future analyses and manuscripts to inform field -Composite cognitive and non-motor scores -Non-motor subtyping -Use of HC cognitive data vs. published norms -Sample size estimates for clinical trials (and other interest of industry) Genetics -Data availability – what are the user types and what type of data do they want? -Is there more that can be done with PPMI data? -What would folks like to see analyzed with genetics? Sleep Working Group -Status of enrollment and follow up-up RBD and hyposmia patients -Publications – submitted, under preparation and planned -Publications of other working groups related to RBD -Proposed projects, wearables and RBD

PPMI Annual Meeting Agenda-2018- Day 2

PPMI Annual Meeting Agenda-2018- Day 2